| EPSRC Reference: |
EP/J501724/1 |
| Title: |
Cell labelling for in vivo use and in-process quality control |
| Principal Investigator: |
Bradley, Professor M |
| Other Investigators: |
|
| Researcher Co-Investigators: |
|
| Project Partners: |
|
| Department: |
Sch of Chemistry |
| Organisation: |
University of Edinburgh |
| Scheme: |
Technology Programme |
| Starts: |
20 April 2012 |
Ends: |
19 April 2015 |
Value (£): |
51,524
|
| EPSRC Research Topic Classifications: |
| Materials Synthesis & Growth |
|
|
| EPSRC Industrial Sector Classifications: |
|
| Related Grants: |
|
| Panel History: |
|
|
Summary on Grant Application Form |
The future use of cells as both therapies and drug discovery tools addresses a huge unmet societal and clinical need
relating to a range of medical conditions, many with no current effective treatment option and representing a huge
disease burden. Over the last 10 years the exciting possibility of creating new therapies using living human cells has
matured to the extent that a small number of therapies exist and an emerging industry can clearly be identified. Cryoskin
is such a product, which is an active treatment for burns and hard to heal wounds (such as leg ulcers). This product
offering uses donor cells grown on selective materials specifically designed to promote cell growth, but then allow release
to the applied site of treatment. The product is being developed in a "spray" format to allow ease of clinical application.
However, it is necessary to be able to track and locate where the cells have been sprayed and to do this using reagents
that are non-toxic, remain within the cells for multiple generations and can be detected simply using a hand-held light
source following or during application.
This proposal is directly aligned to the development of a commercially viable product, with the labelling of Altrika's
Cryoskin product with a GMP synthesised/formulated cellular labelling reagent
which is known to be taken up by cells in a highly efficient fashion. These will then be evaluated by the team from The
Royal London Hospital to ensure that the labelling does not affect cell function and that patient care is improved. This
approach will allowing the delivery of stem cells into the clinical setting with direct tracking of the stem cell derived product
to the point of use.
This proposal brings together a synergistic team of chemists in Edinburgh (who have a long history of cell delivery
expertise) with direct day-to-day interaction with Altrika Limited who are world leading experts in cell based skin wound
care, Roslin Cellab who will assess the nature of the label on stem cell function and clinicians (The Royal London Hospital
and the Trauma Clinical Academic Unit of Barts) who will be using the labelled Cryoskin product.
|
|
Key Findings |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Potential use in non-academic contexts |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Impacts |
|
| Description |
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk |
| Summary |
|
| Date Materialised |
|
|
|
|
Sectors submitted by the Researcher |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
| Project URL: |
|
| Further Information: |
|
| Organisation Website: |
http://www.ed.ac.uk |